Smith Anglin Financial’s Inovio Pharmaceuticals INO Stock Holding History

Smith Anglin Financial’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-833	Closed	-$36K	–	141
2022 Q1	$36K	Buy	+833	New	+$37.5K	0.01%	135

Other funds holding INO

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rafferty Asset Management New York $24.6B AUM 47.06% 1-Year Est. Return

Smith Anglin Financial's INO Position: Q2 2022 in Review

Smith Anglin Financial sold out of Inovio Pharmaceuticals (INO) in Q2 2022, closing a stake of 833 shares — an estimated $36K sold.

Smith Anglin Financial first reported a position in INO in Q1 2022 and held it in 1 quarter. The position peaked at $36K in Q1 2022. 184 funds tracked by Wall St. Rank hold INO as of Q2 2022.

Smith Anglin Financial reported no remaining Inovio Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Smith Anglin Financial sold 833 Inovio Pharmaceuticals shares in Q2 2022, an estimated $36K.
Smith Anglin Financial first reported a position in Inovio Pharmaceuticals in Q1 2022 and held it in 1 quarter.
Smith Anglin Financial's Inovio Pharmaceuticals position peaked at $36K in Q1 2022.
184 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2022.

Based on Smith Anglin Financial's 13F filing for Q2 2022, filed 25 Jul 2022.